| Literature DB >> 34065074 |
Abstract
Stem cell research is essential not only for the research and treatment of human diseases, but also for the genetic preservation and improvement of animals. Since embryonic stem cells (ESCs) were established in mice, substantial efforts have been made to establish true ESCs in many species. Although various culture conditions were used to establish ESCs in cattle, the capturing of true bovine ESCs (bESCs) has not been achieved. In this review, the difficulty of establishing bESCs with various culture conditions is described, and the characteristics of proprietary induced pluripotent stem cells and extended pluripotent stem cells are introduced. We conclude with a suggestion of a strategy for establishing true bESCs.Entities:
Keywords: bovine; embryonic stem cells; extended pluripotent stem cells; induced pluripotent stem cells
Year: 2021 PMID: 34065074 PMCID: PMC8125899 DOI: 10.3390/ijms22095011
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Various characteristics of bovine embryo-derived stem cells.
| Medium | Morphology | Pluripotency | Differentiation | Special | Reference |
|---|---|---|---|---|---|
| FCS, heparin, LIF | mES-like cells | X | Epithelial, fibroblastic, neuron-type cells | With trophoblastic cell | [ |
| FCS | Low cytoplasmic/nuclear ratio | X | in vitro differentiation | Trophecoderm-like cells | [ |
| FBS, LIF | Monolayer cells | X | X | Tetraploid embryos test | [ |
| FBS | Small cytoplasmic/nuclear volume ratio | SSEA-1(+), SSEA-3(+), SSEA-4(+) | in vitro differentiation | Long term culture | [ |
| FBS, LIF, EGF | Small cells compact colony | AP(+), SSEA-1(+), STAT3(+), OCT4(+) SSEA-3(−), SSEA-4(−) | in vitro differentiation | Chimeric test | [ |
| FCS, ITS, LIF, bFGF, EGF, 5-azacytidine | Heterogenetic morphology | REX1(+), OCT4(+), SSEA-4(+) | in vitro differentiation | 5-azacytidine improved pluripotency and ability to differentiate | [ |
| FBS, bFGF, SCF | Bubble-like or TE-like cell | OCT4(+), SSEA-1(+), SSEA4(+), AP(+) | in vitro differentiation | Stem cell factor (SCF), a cytokine that binds to the c-Kit receptor | [ |
| PD0325901, CHIR99021 | Flat-shaped | Naïve state markers(+) Primed state markers(−) | in vitro differentiation | GATA6 and CDX2 expression | [ |
| bFGF, LIF, KSR | Dome-like (early passages) Flat-shaped (late passages) | OCT4(+), SOX2(+), NANOG(+), E-CAD(+), SSEA1(+), SSEA4(+) | in vitro and in vivo differentiation | TE related genes still expressed in CDX2-KD lines | [ |
| PD18435, SU5402, CHIR99021 | Heterogenetic morphology mixed with TE | Naïve state markers(+) Primed state markers (−) | in vitro and in vivo differentiation | OCT4 or Nanog positive cells without CDX2 negative | [ |
| BSA, bFGF, IWR1 | Flat-shaped | Primed state markers(+) | in vitro and in vivo differentiation | X | [ |
FCS: fetal calf serum; LIF: leukemia inhibitory factor; FBS: fetal bovine serum; EGF: Epidermal growth factor; ITS: insulin-transferrin-selenium; bFGF: basic fibroblast growth factor; SCF: stem cell factor; KSR: knockout serum replacement; BSA: bovine serum albumin; IWR1: a Wnt/β-catenin inhibitor.
Various characteristics of bovine induced pluripotent stem cells.
| Medium | Cell Source | Morphology | Reprogramming Factors * | Pluripotency | Differentiation | Reference |
|---|---|---|---|---|---|---|
| KSR, bFGF | MEF | Dome-like | bOSKMLN | AP, OCT4, SOX2, NANOG, SSEA1,4 | in vitro and in vivo | [ |
| PD0325901, CHIR99021, LIF | MEF | Dome-like | bOKSM | AP, OCT4, SOX2, KIF4, SSEA3, 4, TRA-1-60 | in vitro and in vivo | [ |
| FBS, bFGF, LIF | skin fibroblast | Dome-like | hOKMN | AP, OCT4, SOX2, KLF4, C-MYC, NANOG, SSEA1/4 | in vitro and in vivo | [ |
| FBS, bFGF, LIF | MEF | Flat-shaped | hO+pSKM | AP, OCT4, SOX2, KLF4, NANOG, SSEA1 | in vitro and in vivo | [ |
| LIF, FBS | testicular cells | Dome-like | hO | OCT4, SOX2, NANOG, SSEA1, SSEA4 | in vitro and in vivo | [ |
| KSR, bFGF, hLIF | BFF | Dome-like | hOSKM | OCT4, SSEA1, 3, 4, REX1 | in vitro and in vivo | [ |
| CHIR99021, PD0325901, Valproic acid | BFF | Dome-like | bOSKM | OCT4, SOX2, NANOG, KLF4, C-MYC, REX1 | in vitro and in vivo | [ |
| Bio, SC1, 5-AzaC | bAF | Dome-like | hOSKMN | OCT4, NANOG, SSEA-1, SSEA-4, TRA-1-60 | in vitro and in vivo | [ |
| FBS, LIF, bFGF | BFF | Dome-like | bOSKM | OCT4, NANOG, SOX2, SSEA1, SSEA4, AP | in vitro and in vivo | [ |
| KSR, hLIF, CHIR99021, (S)-(+)-dimethindene maleate, and minocycline hydrochloride ** | BFF | Dome-like | bOSKM | OCT4, SOX2, NANOG | in vitro and in vivo Interspecies chimeric embryo test | [ |
* O-OCT4, S-SOX2, K-KLF4, M-CMYC, L-LIN28, N-NANOG. ** Culture conditions for pluripotent stem cells expanded from iPSCs. KSR: knockout serum replacement; bFGF: basic fibroblast growth factor; LIF: leukemia inhibitory factor; FBS: fetal bovine serum; hLIF: human leukemia inhibitory factor; 5-AzaC: 5-Azacytidine; SC1: extracellular signal-regulated kinase/mitogen-activated protein kinase inhibitor; Bio: 6-bromoindirubin-3′-oxime; MEF: mouse embryonic fibroblast; BFF: bovine fetal fibroblast; bAF: bovine adult fibroblast.
Figure 1The relationship between developmental stages and pluripotency states. ICM: inner cell mass; X: active X chromosome; Xi: inactive X chromosome; LIF: leukemia inhibitory factor; 2i: a medium consisting GSK3 and Mek1/2 inhibitors; bFGF: basic fibroblast growth factor; LCDM; a medium consisting of LIF, CHIR99021, (S)-(+)-dimethindene maleate, and minocycline hydrochloride; EPSC: extended pluripotent stem cells; PSC: pluripotent stem cells; iPSC: induced pluripotent stem cells; h: human; m: mouse; p: pig; b: bovine.
Figure 2Applications and future perspectives of pluripotent stem cells in livestock. ICM: inner cell mass; TE: trophectoderm; EPSC: extended pluripotent stem cells; bESC: bovine embryonic stem cells; iPSC: induced pluripotent stem cells.